Arkin Moshe 13D and 13G filings for Eiger BioPharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-08-26 10:01 am Purchase | 2024-08-19 | 13G | Eiger BioPharmaceuticals, Inc. EIGR | Arkin Moshe | 149,371 10.090% | 96,300 (+181.46%) | Filing |
| 2024-07-01 06:47 am Sale | 2024-06-21 | 13D | Eiger BioPharmaceuticals, Inc. EIGR | Arkin Moshe | 53,071 3.580% | -96,300 (-64.47%) | Filing |
| 2023-12-04 06:01 am Sale | 2023-11-14 | 13D | Eiger BioPharmaceuticals, Inc. EIGR | Arkin Moshe | 149,371 10.090% | -33 (-0.02%) | Filing |
| 2023-11-24 06:01 am Unchanged | 2023-11-14 | 13D | Eiger BioPharmaceuticals, Inc. EIGR | Arkin Moshe | 149,404 10.090% | 0 (Unchanged) | Filing |
| 2023-04-18 09:59 am Purchase | 2023-04-10 | 13G | Eiger BioPharmaceuticals, Inc. EIGR | Arkin Moshe | 149,404 10.150% | 58,971 (+65.21%) | Filing |
| 2023-02-02 2:25 pm Purchase | 2022-12-31 | 13G | Eiger BioPharmaceuticals, Inc. EIGR | Arkin Moshe | 90,433 6.160% | 29,559 (+48.56%) | Filing |
| 2022-03-08 08:58 am Purchase | 2022-03-01 | 13G | Eiger BioPharmaceuticals, Inc. EIGR | Arkin Moshe | 60,874 5.380% | 60,874 (New Position) | Filing |